Patent Settlements, Risk, and Competition Mark R. Patterson Fordham University School of Law Patent Settlements: The Issues Beyond the “Reverse Payment”

Slides:



Advertisements
Similar presentations
The Gaming of Pharmaceutical Patents Brief Overview.
Advertisements

What You Need to Know About Biosimilars: Products, Recent Deals, IP Issues and Licensing August 2, 2012 Madison C. Jellins 1.
Prof. David W. Opderbeck Seton Hall University Law School Gibbons Institute of Law, Science & Technology.
1 COPYRIGHT © 2007 West Legal Studies in Business, a part of The Thomson Corporation. Thomson, the Star logo, and West Legal Studies in Business are trademarks.
© 2007 by West Legal Studies in Business / A Division of Thomson Learning CHAPTER 20 Promoting Competition.
IP and Anticompetitive Conduct Intro to IP – Prof. Merges
Antitrust policy Ch17. Government roles to support a modern domestic economy 1- maintain efficiency (prevent excessive abuse of market power.) 2- promote.
A New Pathway for Follow-on Biologics Presented by: Steve Nash May 7, 2010.
Patent Litigaton Strategies in Israel Reuven Behar, partner Fischer Behar Chen & Co.
MAP Pricing Policies Charlie Meyer November 29, 2012.
Texas Health Care Collaboratives Kim Van Winkle Chief, Antitrust Section Spring 2015 Berkeley ACO Workshop May 8, 2015.
H I R S C H & P A R T N E R S A v o c a t S o l i c i t o r R e c h t s a n w a l t Pharmaceutical settlement agreements and competition law A litigation.
Recent Competition Law Developments in the United States and Canada Sandeep Vaheesan Special Counsel American Antitrust Institute November 19, 2013.
Hot Issues in Patent Law Steven G. Saunders
© 2008 International Intellectual Property June 22, 2009 Class 6 Patents: Multilateral Agreements (Paris Convention); Economics of International Patent.
Antitrust Policy & Government Regulation. What is a Trust, and Why Don’t we Want one? Trust defined: a combination of firms aimed at consolidating, coordinating,
Can a Competition Law Violation be Legally Insignificant? A U.S. Perspective Russell W. Damtoft Associate Director Office of International Affairs United.
 “Market power” is the power of company to control the market for its product.  The law does allow for market monopolies when a patent is issued. During.
Competition Policy and Law Presentation to Study Tour for Russian Member Universities of the Virtual Institute Network 26 March 2009.
Intellectual Property and Antitrust Antitrust Basics Lesson III: Intellectual Property November 8, 2006 Sean P. Gates Federal Trade Commission.
© 2008 Dechert LLP Pharma v. Pharma or Pharma & Pharma: The Legal Interface Between the Makers of Original and Copied Versions of Medicines AIPLA Antitrust,
Law Antitrust - Instructor: Dwight Drake Jefferson Parish Hospital Dist. No. 2 v. Hyde (Sup. Ct. 1984) Basic Facts: Exclusive contract between hospital.
IS NEW ZEALAND’S COUNTERFACTUAL TEST COUNTERPRODUCTIVE? Lilla Csorgo Chief Economist, Competition Branch 1.
Patent Cases MM 450 Issues in New Media Theory Steve Baron March 3, 2009.
ABA China Inside and Out September , Beijing The interface between competition law and intellectual property Nicholas Banasevic, DG Competition,
Legal Environment for a New Century. Click your mouse anywhere on the screen when you are ready to advance the text within each slide. After the starburst.
1 The role of Economics in European Competition Enforcement and Policy Damien Neven, Chief Economist * DG COMP, European Commission 5 th International.
Patent Infringement MM450 March 30, What is Patent Infringement? Making, using or selling an invention on which a patent is in force without the.
© 2004 West Legal Studies in Business A Division of Thomson Learning 1 Chapter 26 Antitrust and Monopoly.
9-1 The Cases for Free Trade The first case for free trade is the argument that producers and consumers allocate resources most efficiently when governments.
DMCA Notices and Patents CasesMM450 February, 2008 And now, for something new, useful and not obvious…
COPYRIGHT © 2011 South-Western/Cengage Learning. 1 Click your mouse anywhere on the screen to advance the text in each slide. After the starburst appears,
Patent settlements for medicines -- status under EU and US antitrust law -- Luc Gyselen, Partner Arnold & Porter LLP Brussels Symposium on the Interface.
49-1 Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved.McGraw-Hill/Irwin.
EU-China Workshop on the Chinese Patent Law 24/25 September 2008 Topic IV: Legal Consequences of Invalidity of a Patent Prof. Dr. Christian Osterrieth.
Could a Patent Term Reduction Solve the Software Patent Problem? Brian Love.
Recent FTC Pharmaceutical Cases: Background and Examples Sue H. Kim This presentation was prepared from public sources. The views expressed herein do not.
Charles University – Law Faculty October 2012 © Peter Kolker 2012 Class III
1 How To Find and Read the Law and Live to Tell (and Talk) About It Steve Baron January 29, 2009.
Stephen S. Korniczky Anti-Suit Injunctions – Leveling the Playing Field When Seeking a FRAND License to Standard-Essential.
SMEs and private enforcement of competition law Rachel Burgess Ph:
TRADE SECRETS workshop I © 2009 Prof. Charles Gielen EU-China Workshop on the Protection of Trade Secrets Shanghai June 2009.
Dialogue on Competition Policy and Intellectual Property *
CHAPTER 2 LEGAL INSTITUTIONS
Trademarks III Infringement of Trademarks
EU Competition Rules for Technology Transfer Agreements
BELL QUIZ ON CHAPTER 11 What is it called when a contract has been properly and completely carried out? What does the court ask when determining if the.
Chapter 22 Promoting Competition.
Chapter 27: Antitrust and Monopoly
Looking Over the Legal Edge at Unsuccessful Software Projects
Jonathan R. Nash, Professor of Law, Emory University School of Law
CHAPTER 38 Antitrust.
America Invents Act: Litigation Related Provisions
Dr Pınar Akman Associate Professor School of Law, University of Leeds
How To Find and Read the Law and Live to Tell (and Talk) About It
Class 20 Antitrust, Winter, 2018 Antitrust Injury and Remedies
Thurs., Sept. 5.
Agenda for 14th Class Handouts Sarnoff Assignment for Next Class
Itumeleng Lesofe Competition Commission South Africa
Government and Business
Chapter 40 Corporate Directors, Officers and Shareholders
Pharma Workshop IV Patent Linkage in the USA
Thurs. Sept. 6.
Chapter 11.
4-1 Dispute Resolution and the Courts
2017 AFL-CIO LCC Union Lawyers Conference
The 8th Annual Pharmaceutical Regulatory & Compliance Congress
Antitrust Law and Unfair Trade Practices
Chapter 4: Patents and Trade Secrets in the Information Age.
Update on IP and Antitrust
Presentation transcript:

Patent Settlements, Risk, and Competition Mark R. Patterson Fordham University School of Law Patent Settlements: The Issues Beyond the “Reverse Payment” Cases 59 th Annual Antitrust Spring Meeting March 30, 2011

Two Main Points Patent settlements are different Different from patent litigation, because private agreement Different from many other settlements (e.g., contract), because public implications Risk of litigation is not always bad, if bad means anticompetitive Competition inherently involves risk Whether risk is bad (inefficient?) depends on what parties do in response to risk

Patent Litigation Is Competition Guidelines and courts treat patent protection as a question to be resolved before the nature of underlying product competition is determined An alternative view: patent litigation is another form of competition Patent protection is the right to sue others for infringement Patent protection is patent litigation

Settlement is the Elimination of Competition in Patent Litigation If we treat patent litigation as a competitive process, settlement is an elimination of competition (U.S. v. Singer Mfg. Co.) Even if litigation is protected by Noerr- Pennington doctrine, settlement is not Private agreement, not government act Question is not whether litigation is sham

When Do Patent Settlements Produce Procompetitive Effects? If patent settlements eliminate competition, when is that loss balanced by a gain? Generally, those who advocate little scrutiny of settlements point to the elimination of risk as a gain But risk is always present with competition, and need not be anticompetitive

Allocation of Risk and Competition Assume two competitors in a (non-IP) market where only one will prevail, and we know, or think we know, which it will be Analogous to patent context An allocation of the market would allocate the risk of success But an allocation of the market would also (presumably) be per se illegal

Only Some Risk Creates Inefficiencies In previous network/scale economy example, firms (presumably) respond to the risk by seeking to better serve consumers In contrast, in exclusive-dealing agreements, courts often say reduction of risk is efficient But dealing with risk in that context involves precautions (hedging, contractual protections) that do not benefit consumers One way to consider competitive effect of risk: How do firms respond to the risk?

Are Costs of Addressing Risk in Infringement Context Inefficient? Patentee’s responses to patent litigation risk: Using first-mover advantage and effort to establish brand loyalty: procompetitive Bringing infringement suit: litigation costs may be inefficient, but are part of patent law, and attorney’s fees can be recovered If concern is expenditure to prevent incorrect jury verdict, we don’t generally allow private parties to preempt even incorrect decisions Cf. Professional Engineers, IFD

Are Costs of Addressing Risk in Infringement Context Inefficient? Alleged infringer’s response to patent litigation risk: Seeking invalidation of patent, which is procompetitive, or at least encouraged by Supreme Court If concern is rent-seeking, possibility of settlement seems likely to encourage rather than discourage

Why Ever Allow Patent Settlements? We don’t require firms to take on risk in new markets So we shouldn’t require firm that has been infringing unknowingly to litigate infringement suit (i.e., effectively enter another market) Same for firms that haven’t entered market But firm alleged to have infringed with knowledge of patent has shown willingness to litigate Unless new evidence, grant of injunction, etc. Tolerance for settlement should reflect not risk, but unanticipated risk Does seeking patent show willingness to litigate?

Why Is Hatch-Waxman Different? As courts and commentators note, Hatch- Waxman changed the risk calculus for generics But this cannot have been a surprise to Congress There is no reason to think that any deviation from the “normal” allocation of risk/cost/reward is the correct one In Hatch-Waxman context, generic manufacturer elects to enter litigation “market” by filing Paragraph IV certification Similar to declaratory judgment action Was Congress anticipating litigation?